USASpending / award record
DHA STTR PHASE II PROPOSAL H2-0803, TITLED "DEVELOPMENT OF ANTIBODY TREATMENT OF MDR ESKAPE PATHOGEN, P. AERUGINOSA.", MEDICAL R&D CONTRACT.
Source: USASpending · CONT_AWD_HT942525C0011_9700_-NONE-_-NONE- · As of 2026-07-14 · Last synced 2026-11-01
Dates reflect the source record. Options and extensions exist; an end date does not establish that a contract will be recompeted, renewed, or terminated.
- source record id
- CONT_AWD_HT942525C0011_9700_-NONE-_-NONE-
- generated unique award id
- CONT_AWD_HT942525C0011_9700_-NONE-_-NONE-
- source
- USASpending
- award id piid
- HT942525C0011
- vendor name as awarded
- FABRICO TECHNOLOGY, INC.
- vendor uei
- YMAJVR21PC43
- agency name
- Department of Defense
- sub agency
- Defense Health Agency
- contract title or description
- DHA STTR PHASE II PROPOSAL H2-0803, TITLED "DEVELOPMENT OF ANTIBODY TREATMENT OF MDR ESKAPE PATHOGEN, P. AERUGINOSA.", MEDICAL R&D CONTRACT.
- naics code
- 541715
- naics description
- RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- psc code
- AN12
- texas nigp code
- Not published
- value obligated
- 1299972
- Total / ceiling as published (not obligated)
- Not published
- pop start date
- 2025-03-12T05:00:00.000Z
- expiry date
- 2027-07-11T05:00:00.000Z
- place of performance state
- TX
- recipient location state
- TX
- set aside type
- SMALL BUSINESS SET ASIDE - TOTAL
- source as of
- 2026-07-14T05:00:00.000Z
- last synced
- 2026-11-01T05:00:00.000Z
- published
- true
- Source expiry field
- Period of performance current end date (USASpending)